Affimed N.V. Overview
Pro stress-test →Affimed N.V. is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's Innate Cell Engagers (ICE®), generated from its proprietary ROCK® platform, are bispecific antibodies which target innate immune cells like natural killer (NK) cells and macrophages, to destroy tumor cells.
Strategic Profile
Pro stress-test →Affimed has three active clinical programs focused on solid tumors and blood cancers, with lead candidate Acimtamig (AFM13) in development for patients with CD30-positive lymphomas. The company has collaborations with Artiva Biotherapeutics, Roivant Sciences Ltd., and Genentech for developing and commercializing novel ICE molecules in oncology.
Competitive Landscape
Pro stress-test →Affimed competes through strategic partnerships and collaboration agreements with key players like Genentech for NK cell engager-based immunotherapeutics to treat multiple cancers. The company's main competition includes established NK cell therapy players (Artiva Biotherapeutics), bispecific antibody developers, and conventional checkpoint inhibitor producers. Affimed's differentiation rests on its tetravalent bispecific design and innate immune focus rather than adaptive T-cell approaches.
Industry Context
Affimed N.V. operates in Biopharmaceuticals - Immuno-Oncology.
Key facts
Founded: 2000 · Headquarters: Mannheim, Germany · Employees: 76 · Market cap: $2.975M